1-15 of 15
Pascale André, PhD
Close
Sort by
Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Norbert Vey, Pierre-Yves Dumas, MD, Christian Recher, MD PhD, Lauris Gastaud, MD, Bruno Lioure, MD, Claude-Eric Bulabois, MD, Cecile Pautas, Jean-Pierre Marolleau, MD PhD, Stéphane Leprêtre, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD, Yosr Hicheri, Caroline Bonmati, MD, Bruno Quesnel, MD PhD, Philippe Rousselot, Sylvie Castaigne, MD PhD, Eric Jourdan, MD, Jean Valère Malfuson, Gaelle Guillerm, MD, Jean Henri Bouhris, Mario Ojeda, MD, Mathilde Hunault, MD PhD, Norbert Ifrah, MD PhD, Claude Gardin, MD PhD, Andre Delannoy, MD, Lucile Beautier, Carine Paturel, PhD, Pascale Andre, PhD, Robert Zerbib, Claude Preudhomme, PharmD, PhD, Antoine Toubert, MD PhD, Nicolas Dulphy, PhD, Daniel Olive, MD PhD, Arnaud Pigneux, MD, Herve Dombret, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 889.
https://doi.org/10.1182/blood.V130.Suppl_1.889.889
Published: 2017
Journal Articles

Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab

Caroline Sola, PhD, Mathieu Blery, PhD, Cécile Bonnafous, PhD, Elodie Bonnet, Nicolas Fuseri, Robert F Graziano, PhD, Yannis Morel, PhD, Pascale André, PhD
Journal: Blood
Blood (2014) 124 (21): 4711.
https://doi.org/10.1182/blood.V124.21.4711.4711
Published: 2014
Journal Articles

Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab

Michael Robbins, BS, Maria Jure-Kunkel, DVM, PhD, Gennaro Dito, BS, Pascale Andre, PhD, Hui-fen Zhang, PhD, Natalie Bezman, PhD, Robert F Graziano, PhD
Journal: Blood
Blood (2014) 124 (21): 4717.
https://doi.org/10.1182/blood.V124.21.4717.4717
Published: 2014
Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD
Journal: Blood
Blood (2013) 122 (21): 4417.
https://doi.org/10.1182/blood.V122.21.4417.4417
Published: 2013
Journal Articles

Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia

Norbert Vey, MD, Jean-Henri Bourhis, MD, PhD, Christian Recher, MD PhD, Anne Etienne, MD, Aude Charbonnier, MD, PhD, Pascale Andre, PhD, Jérôme Rey, MD, Franceline Calmels, Robert Zerbib, Renaud Buffet, MD, Thomas Prebet, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2696.
https://doi.org/10.1182/blood.V122.21.2696.2696
Published: 2013
Journal Articles

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Craig C Hofmeister, MD, Munshi C Nikhil, MD, Sundar Jagannath, MD, Yvonne A Efebera, MD, Gary Spitzer, MD, Robert Zerbib, Pascale Andre, PhD, Shawna Oxier, Michael A. Caligiuri, MD
Journal: Blood
Blood (2013) 122 (21): 3181.
https://doi.org/10.1182/blood.V122.21.3181.3181
Published: 2013
Journal Articles

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Gary Spitzer, MD, Craig C. Hofmeister, MD, Robert Zerbib, Pascale Andre, PhD, Yvonne A Efebera, M.D., Shawna Oxier, Michael A. Caligiuri, M.D.
Journal: Blood
Blood (2012) 120 (21): 4058.
https://doi.org/10.1182/blood.V120.21.4058.4058
Published: 2012
Journal Articles

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Jerome Rey, MD, Nicolas Anfossi, PhD, Pascale Andre, PhD, Jean-Marie Boher, Florence Orlanducci, Violette Breso, Valentine Perri, Thomas Prebet, MD, PhD, Aude Charbonnier, MD, PhD, Eloïse Perrot, Francois Romagne, PhD, Norbert Vey, MD, Daniel Olive, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2189.
https://doi.org/10.1182/blood.V118.21.2189.2189
Published: 2011
Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2011) 118 (21): 1865.
https://doi.org/10.1182/blood.V118.21.1865.1865
Published: 2011
Journal Articles

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

Daniel Olive, MD, PhD, Nicolas Anfossi, Pascale Andre, PhD, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Eloise Perrot, Francois Romagne, PhD, Norbert Vey
Journal: Blood
Blood (2009) 114 (22): 1653.
https://doi.org/10.1182/blood.V114.22.1653.1653
Published: 2009
Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD
Journal: Blood
Blood (2009) 114 (22): 4641.
https://doi.org/10.1182/blood.V114.22.4641.4641
Published: 2009
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Don Benson, MD, PhD, Craig C. Hofmeister, MD, Swaminathan Padmanabhan, MD, MBBS, Rafat Abonour, Attaya Suvannasankha, MD, Alain Mita, Patrick Squiban, MD, Megan K Smith, MS, CNP, RN, Courtney E Bakan, Marc Marzetto, Pascale Andre, PhD, Jerome Tollier, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2880.
https://doi.org/10.1182/blood.V114.22.2880.2880
Published: 2009
Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 3870.
https://doi.org/10.1182/blood.V114.22.3870.3870
Published: 2009
Journal Articles

Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.

Nicolai Wagtmann, PhD, Pascale Andre, PhD, Stefan Zahn, PhD, Pieter Spee, PhD, Nicolas Anfossi, PhD, Laurent Gauthier, PhD, Bradley W. Blaser, PhD, Michael A. Caligiuri, MD, Marusca Capanni, Loredana Ruggeri, PhD, Andrea Velardi, MD, Francois Romagne, PhD
Journal: Blood
Blood (2007) 110 (11): 582.
https://doi.org/10.1182/blood.V110.11.582.582
Published: 2007